153 related articles for article (PubMed ID: 9258255)
1. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.
Hsu DW; Louis DN; Efird JT; Hedley-Whyte ET
J Neuropathol Exp Neurol; 1997 Aug; 56(8):857-65. PubMed ID: 9258255
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.
Ralte AM; Sharma MC; Karak AK; Mehta VS; Sarkar C
Pathol Oncol Res; 2001; 7(4):267-78. PubMed ID: 11882906
[TBL] [Abstract][Full Text] [Related]
3. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
4. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma.
McKeever PE; Strawderman MS; Yamini B; Mikhail AA; Blaivas M
J Neuropathol Exp Neurol; 1998 Oct; 57(10):931-6. PubMed ID: 9786243
[TBL] [Abstract][Full Text] [Related]
5. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.
Uematsu M; Ohsawa I; Aokage T; Nishimaki K; Matsumoto K; Takahashi H; Asoh S; Teramoto A; Ohta S
J Neurooncol; 2005 May; 72(3):231-8. PubMed ID: 15937645
[TBL] [Abstract][Full Text] [Related]
9. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
Heesters MA; Koudstaal J; Go KG; Molenaar WM
J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
13. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.
Rodríguez-Pereira C; Suárez-Peñaranda JM; Vázquez-Salvado M; Sobrido MJ; Abraldes M; Barros F; Forteza J
J Neurosurg Sci; 2000 Dec; 44(4):203-9; discussion 209-10. PubMed ID: 11327289
[TBL] [Abstract][Full Text] [Related]
14. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
[TBL] [Abstract][Full Text] [Related]
15. Practical value of MIB-1 index in predicting behavior of astrocytomas.
Ambroise MM; Khosla C; Ghosh M; Mallikarjuna VS; Annapurneswari S
Indian J Pathol Microbiol; 2011; 54(3):520-5. PubMed ID: 21934213
[TBL] [Abstract][Full Text] [Related]
16. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
17. Proliferation index as a predictor of prognosis in malignant gliomas of childhood.
Pollack IF; Campbell JW; Hamilton RL; Martinez AJ; Bozik ME
Cancer; 1997 Feb; 79(4):849-56. PubMed ID: 9024724
[TBL] [Abstract][Full Text] [Related]
18. Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas.
Haapasalo J; Mennander A; Helen P; Haapasalo H; Isola J
J Clin Pathol; 2005 Mar; 58(3):263-8. PubMed ID: 15735157
[TBL] [Abstract][Full Text] [Related]
19. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
20. Relationship of intraoperative ultrasound characteristics with pathological grades and Ki-67 proliferation index in intracranial gliomas.
Baskan O; Silav G; Sari R; Canoz O; Elmaci I
J Med Ultrason (2001); 2015 Apr; 42(2):231-7. PubMed ID: 26576577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
